Exploring Triplet Therapies in Frontline Acute Myeloid Leukemia Management

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss the rationale for investigating triplet therapies in acute myeloid leukemia.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, detail populations in AML that could derive benefit from triplet therapies.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data for venetoclax plus azacitidine vs induction chemotherapy in newly diagnosed, fit AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential triplet strategies with menin inhibitors for KMT2A-rearranged AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential treatment strategies in AML following triplet therapy and transplant.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential dose modification approaches for the use of triplet therapy in AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight other key AML data from the 2025 ASH Annual Meeting.